Interactive effect of APOE genotype and blood pressure on cognitive decline: The PATH through life study

Journal of Alzheimer's Disease

Volumn 44, Issue 4, 2015, Pages 1087-1098

  Andrews, Shea ^a   Das, Debjani ^a   Anstey, Kaarin J ^b   Easteal, Simon ^a  

^a Biology and Environment   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Aging; apolipoprotein E; blood pressure; cognitive decline; gene environment interaction; hypertension

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELE; APOE GENE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; COGNITION ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; EPISODIC MEMORY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; PRIORITY JOURNAL; VERBAL BEHAVIOR; WORKING MEMORY; AGED; COMPLICATION; GENETICS; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; RECALL; RISK FACTOR;

AGED; APOLIPOPROTEINS E; BLOOD PRESSURE; COGNITION DISORDERS; GENOTYPE; HUMANS; HYPERTENSION; MENTAL RECALL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 84923314136     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140630     Document Type: Article

References (60)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, SmallGW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
2. Henderson AS, Easteal S, Jorm AF, Mackinnon AJ, Korten AE, Christensen H, Croft L, Jacomb PA (1995) Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 346, 1387-1390.
3. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA 278, 1349-1356.
4. Davies G, Harris SE, Reynolds CA, Payton A, Knight HM, Liewald DC, Lopez LM, Luciano M, Gow AJ, Corley J, Henderson R, Murray C, Pattie A, Fox HC, Redmond P, LutzMW, Chiba-Falek O, Linnertz C, Saith S, Haggarty P, McNeill G, Ke X, Ollier W, Horan M, Roses AD, Ponting CP, Porteous DJ, Tenesa A, Pickles A, Starr JM, Whalley LJ, Pedersen NL, Pendleton N, Visscher PM, Deary IJ (2014) A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. Mol Psychiatry 19, 76-87.
5. Small BJ, Rosnick CB, Fratiglioni L, Bäckman L (2004) Apolipoprotein E and Cognitive Performance: A Meta-Analysis. Psychol Aging 19, 592-600.
6. Wisdom NM, Callahan JL, Hawkins KA (2011) The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. Neurobiol Aging 32, 63-74.
7. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PCJ, Rimmler JB, Locke PA, Conneally PM, Schmader KE (1994) Protective effect of apolipoproteinEtype 2 allele for late onset Alzheimer disease. Nat Genet 7, 180-184.
8. Wilson RS, Bienias JL, Berry-Kravis E, Evans DA, Bennett DA (2002) The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry 73, 672-677.
9. Berlau DJ, Corrada MM, Head E, Kawas CH (2009) APOE-2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 72, 829-834.
10. Bunce D, Bielak AAM, Anstey KJ, Cherbuin N, Batterham PJ, Easteal S (2014) APOE genotype and cognitive change in young, middle-aged, and older adults living in the community. J Gerontol A Biol Sci Med Sci 69, 379-386.
11. Bunce D, Anstey KJ, Burns R, Christensen H, Easteal S (2011) Does possession of apolipoprotein E-4 benefit cognitive function in healthy young adults? Neuropsychologia 49, 1693-1697.
12. Jorm AF, Mather KA, Butterworth P, Anstey KJ, Christensen H, Easteal S (2007)APOEgenotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 21, 1-8.
13. Christensen H, Batterham PJ, Mackinnon AJ, Jorm AF, Mack HA, Mather KA, Anstey KJ, Sachdev PS, Easteal S (2008) The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample. BMC Geriatr 8, 14.
14. Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
15. Novak V, Hajjar I (2010) The relationship between blood pressure and cognitive function. Nat Rev Cardiol 7, 686-698.
16. Gasecki D, Kwarciany M, Nyka W, Narkiewicz K (2013) Hypertension, brain damage and cognitive decline. Curr Hypertens Rep 15, 547-558.
17. Tzourio C, Dufouil C, Ducimetíere P, Alpárovitch A (1999) Cognitive decline in individuals with high blood pressure A longitudinal study in the elderly. Neurology 53, 1948-1952.
18. Yasar S, Ko JY, Nothelle S, Mielke MM, Carlson MC (2011) Evaluation of the effect of systolic blood pressure and pulse pressure on cognitive function: The Women's Health and Aging Study II. PLoS One 6, e27976.
19. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145.
20. Qiu C, Winblad B, Fratiglioni L (2009) Lowdiastolic pressure and risk of dementia in very old people: A longitudinal study. Dement Geriatr Cogn Disord 28, 213-219.
21. Thorvaldsson V, Skoog I, Hofer SM, Börjesson-Hanson A, Östling S, Sacuiu S, Johansson B (2012) Nonlinear blood pressure effects on cognition in old age: Separating betweenperson and within-person associations. Psychol Aging 27, 375-383.
22. Herbert LE, Scherr PA, Bennett DA, Bienias JL, Wilson RS, Morris MC, Evans DA (2004) Blood pressure and late-life cognitive function change: A biracial longitudinal population study. Neurology 62, 2021-2024.
23. Solfrizzi V, Panza F, Colacicco AM, D'introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A (2004) Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63, 1882-1891.
24. Payton A (2009) The impact of genetic research on our understanding of normal cognitive ageing: 1995 to 2009. Neuropsychol Rev 19, 451-477.
25. Niu W, Qi Y, Qian Y, Gao P, Zhu D (2009) The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: A meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 32, 1060-1066.
26. Sudlow C, González NAM, Kim J, Clark C (2006) Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17, 965 controls. Stroke 37, 364-370.
27. Hamzi K, Tazzite A, Nadifi S (2011) Large-scale metaanalysis of genetic studies in ischemic stroke: Five genes involving 152, 797 individuals. Indian J Hum Genet 17, 212-217.
28. Song Y, Stampfer MJ, Liu S (2004) Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141, 137-147.
29. Khan TA, Shah T, Prieto D, Zhang W, Price J, Fowkes GR, Cooper J, Talmud PJ, Humphries SE, Sundstrom J, Hubacek JA, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Abdollahi MR, Slooter AJC, Szolnoki Z, Sandhu M, Wareham N, Frikke-Schmidt R, Tybjaerg-Hansen A, Fillenbaum G, Heijmans BT, Katsuya T, Gromadzka G, Singleton A, Ferrucci L, Hardy J, Worrall B, Rich SS, Matarin M, Whittaker J, Gaunt TR, Whincup P, Morris R, Deanfield J, Donald A, Davey Smith G, Kivimaki M, Kumari M, Smeeth L, Khaw K-T, Nalls M, Meschia J, Sun K, Hui R, Day I, Hingorani AD, Casas JP (2013) Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14, 015 stroke cases and pooled analysis of primary biomarker data from up to 60, 883 individuals. Int J Epidemiol 42, 475-492.
30. Eichner JE, Dunn ST, Perveen G (2002) Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 155, 487-495.
31. Lahoz C, Schaefer EJ, Cupples LA, Wilson PW, Levy D, Osgood D, Parpos S, Pedro-Botet J, Daly JA, Ordovas JM (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154, 529-537.
32. Kofler BM, Miles EA, Curtis P, Armah CK, Tricon S, Grew J, Napper FL, Farrell L, Lietz G, Packard CJ, Caslake MJ, Mathers JC, Williams CM, Calder PC, Minihane AM (2012) ApolipoproteinEgenotype and the cardiovascular disease risk phenotype: Impact of sex and adiposity (the FINGEN study). Atherosclerosis 221, 467-470.
33. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1996) Cerebrovascular disease, the apolipoprotein-4 allele, and cognitive decline in a community-based study of elderly men. Stroke 27, 2230-2235.
34. Bangen KJ, Beiser A, Delano-Wood L, Nation DA, Lamar M, Libon DJ, Bondi MW, Seshadri S, Wolf PA, Au R (2013) APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis 22, 1361-1369.
35. Kang JH, Logroscino G, De Vivo I, Hunter D, Grodstein F (2005) Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging 26, 475-484.
36. Yasuno F, Tanimukai S, Sasaki M, Ikejima C, Yamashita F, Kodama C, Hidaka S, Mizukami K, Asada T (2012) Effect of plasma lipids, hypertension and APOE genotype on cognitive decline. Neurobiol Aging 33, 2633-2640.
37. de Frias CM, Schaie KW, Willis SL (2014) Hypertension moderates the effect of APOE on 21-year cognitive trajectories. Psychol Aging 29, 431-439.
38. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C (2011) Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77, 461-468.
39. Carmelli D, Swan GE, Reed T, Miller B, Wolf PA, Jarvik GP, Schellenberg GD (1998) Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology 50, 1580-1585.
40. Caselli RJ, Dueck AC, Locke DEC, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM (2011) Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology 76, 1078-1084.
41. Knopman DS, Mosley TH, Catellier DJ, Coker LH (2009) Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study. Alzheimers Dement 5, 207-214.
42. Anstey KJ, Christensen H, Butterworth P, Easteal S, Mackinnon A, Jacomb T, Maxwell K, Rodgers B, Windsor T, Cherbuin N, Jorm AF (2012) Cohort profile: The PATH through life project. Int J Epidemiol 41, 951-960.
43. O'Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, Lucas JA (2008) Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol 65, 963-967.
44. Roth PL (1994) Missing data:Aconceptual reviewfor applied psychologists. Pers Psychol 47, 537-560.
45. Zheng L, Sun Z, Li J, Zhang R, Zhang X, Liu S, Li J, Xu C, Hu D, Sun Y (2008) Pulse pressure and mean arterial pressure in relation to ischemic stroke among patients with uncontrolled hypertension in rural areas of China. Stroke 39, 1932-1937.
46. Martin A, Rief W, Klaiberg A, Braehler E (2006) Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. Gen Hosp Psychiatry 28, 71-77.
47. Smith A (2002) Symbol Digit Modalities Test: Manual, Western Psychological Corporation, Los Angeles.
48. Delis DC, Kramer JH, Kaplan E, Ober BA (1987) California Verbal Learning Test, Psychological Corporation, San Antonio.
49. Wechsler D (1945) A standardized memory scale for clinical use. J Psychol 19, 87-95.
50. Baddeley A, Emslie H, Nimmo-Smith I (1993) The Spot-the-Word test: A robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol 32, 55-65.
51. Singer JD, Willett JB (2003) Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence, Oxford University Press, New York.
52. Donohue MC, Gamst AC, Edland SD, Donohue M (2013) Package "longpower." Biometrics 53, 937-947.
53. Scherbaum CA, Ferreter JM (2009) Estimating statistical power and required sample sizes for organizational research using multilevel modeling. Organ Res Methods 12, 347-367.
54. Richards M, Sacker A (2003) Lifetime antecedents of cognitive reserve. J Clin Exp Neuropsychol 25, 614-624.
55. Meng X, D'ArcyC (2012) Education and dementia in the context of the cognitive reserve hypothesis: A systematic review with meta-analyses and qualitative analyses. PLoS One 7, e38268.
56. Barulli D, Stern Y (2013) Efficiency, capacity, compensation, maintenance, plasticity: Emerging concepts in cognitive reserve. Trends Cogn Sci 17, 502-509.
57. Hofer SM, Christensen H, Mackinnon AJ, Korten AE, Jorm AF, Henderson AS, Easteal S (2002) Change in cognitive functioning associated with apoE genotype in a community sample of older adults. Psychol Aging 17, 194-208.
58. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, Berry-Kravis E, Bach J, Fox JH, Evans DA, Bennett DA (2002) The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 59, 1154-1160.
59. Low L-F, Yap MHW, Brodaty H (2010) Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. Neurosci Biobehav Rev 34, 408-437.
60. Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA, Bennett DA (2013) Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 74, 478-489.